These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 1759539

  • 1. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F.
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
    [Abstract] [Full Text] [Related]

  • 2. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
    Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I.
    Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
    [Abstract] [Full Text] [Related]

  • 3. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N.
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V, Simic M, Ilic L, Micic D, Damjanovic S, Djurovic M, Obradovic S, Dieguez C, Casanueva F.
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [Abstract] [Full Text] [Related]

  • 6. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
    Beckers A, Petrossians P, Abs R, Flandroy P, Stadnik T, de Longueville M, Lancranjan I, Stevenaert A.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I.
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [Abstract] [Full Text] [Related]

  • 9. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, Lombardi G, Schettini G.
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [Abstract] [Full Text] [Related]

  • 10. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
    Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP.
    J Endocrinol Invest; 1996 Dec; 19(7):472-9. PubMed ID: 8884542
    [Abstract] [Full Text] [Related]

  • 11. Parlodel LAR in the treatment of macroprolactinomas.
    Kocijancic A, Prezelj J, Vrhovec I, Lancranjan I.
    Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
    [Abstract] [Full Text] [Related]

  • 12. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G.
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [Abstract] [Full Text] [Related]

  • 13. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL, García-Luna PP, Leal-Cerro A, Cortés A, Trujillo F, Villamil F, Vaquero F, Revuelta M, Astorga R.
    Med Clin (Barc); 1994 Jun 11; 103(2):59-64. PubMed ID: 8051973
    [Abstract] [Full Text] [Related]

  • 14. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Jun 11; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 15. New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Jun 11; 43(3):234-41. PubMed ID: 1345564
    [Abstract] [Full Text] [Related]

  • 16. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E, Camanni F.
    Drugs; 1996 Jun 11; 51(6):954-65. PubMed ID: 8736617
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T, Arikan E, Tasan E, Hatemi H.
    Intern Med; 2001 Sep 11; 40(9):857-61. PubMed ID: 11579944
    [Abstract] [Full Text] [Related]

  • 18. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
    Ciccarelli E, Ghigo E, Mazza E, Andreis M, Massara F, Lancranjan I, Camanni F.
    J Endocrinol Invest; 1987 Apr 11; 10(2):179-82. PubMed ID: 3584856
    [Abstract] [Full Text] [Related]

  • 19. Primary treatment of macroprolactinomas with Parlodel LAR.
    van 't Verlaat JW, Lancranjan I, Hendriks MJ, Croughs RJ.
    Acta Endocrinol (Copenh); 1988 Sep 11; 119(1):51-5. PubMed ID: 3414319
    [Abstract] [Full Text] [Related]

  • 20. Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
    Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser GM, Grossman A.
    Fertil Steril; 1989 Dec 11; 52(6):930-5. PubMed ID: 2591571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.